{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:46:56Z","timestamp":1788299216883,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","award":["2023AH040380, KJ2021ZD0031"],"award-info":[{"award-number":["2023AH040380, KJ2021ZD0031"]}],"id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","award":["2023AH040380, KJ2021ZD0031"],"award-info":[{"award-number":["2023AH040380, KJ2021ZD0031"]}],"id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Cultivation Program of The Second Affiliated Hospital of Anhui Medical University","award":["2021LCYB08, 2020LCD14"],"award-info":[{"award-number":["2021LCYB08, 2020LCD14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06136-7","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T16:31:47Z","timestamp":1740501107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["157Gd-DOTA-PSMA as theranostic bio-gadolinium agent for prostate cancer targeted gadolinium neutron capture therapy"],"prefix":"10.1007","volume":"151","author":[{"given":"Liang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"6136_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2017.01.004","author":"F Ali","year":"2020","unstructured":"Ali F, Hosmane SN, Zhu Y (2020) Boron chemistry for medical applications. Molecules. https:\/\/doi.org\/10.1016\/j.addr.2017.01.004","journal-title":"Molecules"},{"key":"6136_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2017.01.004","volume":"109","author":"C Allen","year":"2017","unstructured":"Allen C, Her S, Jaffray DA (2017) Radiotherapy for cancer: present and future. Adv Drug Deliv Rev 109:1\u20132","journal-title":"Adv Drug Deliv Rev"},{"key":"6136_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.apradiso.2009.03.102","volume":"67","author":"RF Barth","year":"2009","unstructured":"Barth RF (2009) Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 67:S3\u2013S6","journal-title":"Appl Radiat Isot"},{"key":"6136_CR4","first-page":"35","volume":"38","author":"RF Barth","year":"2018","unstructured":"Barth RF, Mi P, Yang W (2018) Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond) 38:35","journal-title":"Cancer Commun (Lond)"},{"key":"6136_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/cac2.12582","volume":"44","author":"RF Barth","year":"2024","unstructured":"Barth RF, Gupta N, Kawabata S (2024) Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT. Cancer Commun (Lond) 44:893\u2013909","journal-title":"Cancer Commun (Lond)"},{"key":"6136_CR6","first-page":"141","volume":"38","author":"J Capala","year":"2023","unstructured":"Capala J, Hong JA, Vikram B, Coleman CN (2023) Neutron capture therapy: the promise of novel agents and medical facility-based neutron sources. Cancer Biother Radiopharm 38:141\u2013142","journal-title":"Cancer Biother Radiopharm"},{"key":"6136_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1179\/016164105X17206","volume":"27","author":"G De Stasio","year":"2005","unstructured":"De Stasio G, Rajesh D, Casalbore P, Daniels MJ, Erhardt RJ, Frazer BH, Wiese LM, Richter KL, Sonderegger BR, Gilbert B, Schaub S, Cannara RJ, Crawford JF, Gilles MK, Tyliszczak T, Fowler JF, Larocca LM, Howard SP, Mercanti D, Mehta MP, Pallini R (2005) Are gadolinium contrast agents suitable for gadolinium neutron capture therapy? Neurol Res 27:387\u2013398","journal-title":"Neurol Res"},{"key":"6136_CR8","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.2967\/jnumed.117.191023","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Rahbar K, Herrmann K, Kratochwil C, Eiber M (2017) 177Lu-PSMA radioligand therapy for prostate cancer. J Nucl Med 58:1196\u20131200","journal-title":"J Nucl Med"},{"key":"6136_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2023.07.001","volume":"30","author":"L Gu","year":"2023","unstructured":"Gu L, Li M, Li CM, Haratipour P, Lingeman R, Jossart J, Gutova M, Flores L, Hyde C, Kenji\u0107 N, Li H, Chung V, Li H, Lomenick B, Von Hoff DD, Synold TW, Aboody KS, Liu Y, Horne D, Hickey RJ, Perry JJP, Malkas LH (2023) Small molecule targeting of transcription-replication conflict for selective chemotherapy. Cell Chem Biol 30:1235-1247.e6","journal-title":"Cell Chem Biol"},{"key":"6136_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13014-021-01939-7","volume":"16","author":"H He","year":"2021","unstructured":"He H, Li J, Jiang P, Tian S, Wang H, Fan R, Liu J, Yang Y, Liu Z, Wang J (2021) The basis and advances in clinical application of boron neutron capture therapy. Radiat Oncol 16:216","journal-title":"Radiat Oncol"},{"key":"6136_CR11","doi-asserted-by":"publisher","first-page":"12653","DOI":"10.1039\/C8RA00553B","volume":"8","author":"SL Ho","year":"2018","unstructured":"Ho SL, Cha H, Oh IT, Jung KH, Kim MH, Lee YJ, Miao X, Tegafaw T, Ahmad MY, Chae KS, Chang Y, Lee GH (2018) Magnetic resonance imaging, gadolinium neutron capture therapy, and tumor cell detection using ultrasmall Gd2O3 nanoparticles coated with polyacrylic acid-rhodamine B as a multifunctional tumor theragnostic agent. RSC Adv 8:12653\u201312665","journal-title":"RSC Adv"},{"key":"6136_CR12","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1021\/acsomega.1c06603","volume":"7","author":"SL Ho","year":"2022","unstructured":"Ho SL, Yue H, Tegafaw T, Ahmad MY, Liu S, Nam SW, Chang Y, Lee GH (2022) Gadolinium neutron capture therapy (GdNCT) agents from molecular to nano: current status and perspectives. ACS Omega 7:2533\u20132553","journal-title":"ACS Omega"},{"key":"6136_CR13","doi-asserted-by":"publisher","DOI":"10.1088\/1468-6996\/12\/4\/044607","volume":"12","author":"Y Horiguchi","year":"2011","unstructured":"Horiguchi Y, Kudo S, Nagasaki Y (2011) Gd@C82 metallofullerenes for neutron capture therapy-fullerene solubilization by poly (ethylene glycol)-block-poly (2-(N, N-diethylamino)ethyl methacrylate) and resultant efficacy in vitro. Sci Technol Adv Mater 12:044607","journal-title":"Sci Technol Adv Mater"},{"key":"6136_CR14","doi-asserted-by":"publisher","DOI":"10.1142\/8056","author":"NS Hosmane","year":"2012","unstructured":"Hosmane NS, Maguire JA, Zhu Y, Takagaki M (2012) Boron and gadolinium neutron capture therapy for cancer treatment. World Scient. https:\/\/doi.org\/10.1142\/8056","journal-title":"World Scient"},{"key":"6136_CR15","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.3390\/pharmaceutics15122663","volume":"15","author":"J J\u00e4rvinen","year":"2023","unstructured":"J\u00e4rvinen J, Pulkkinen H, Rautio J, Timonen JM (2023) Amino acid-based boron carriers in boron neutron capture therapy (BNCT). Pharmaceutics 15:2663","journal-title":"Pharmaceutics"},{"key":"6136_CR16","doi-asserted-by":"publisher","first-page":"3727109","DOI":"10.1155\/2018\/3727109","volume":"2018","author":"KH Jung","year":"2018","unstructured":"Jung KH, Park JA, Kim JY, Kim MH, Oh S, Kim HK, Choi EJ, Kim HJ, Do SH, Lee KC, Kim KM, Lee YJ, Chang Y (2018) Image-guided neutron capture therapy using the gd-do3a-bta complex as a new combinatorial treatment approach. Contrast Media Mol Imag 2018:3727109","journal-title":"Contrast Media Mol Imag"},{"key":"6136_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1021\/bc010002o","volume":"12","author":"H Kobayashi","year":"2001","unstructured":"Kobayashi H, Kawamoto S, Saga T, Sato N, Ishimori T, Konishi J, Ono K, Togashi K, Brechbiel MW (2001) Avidin-dendrimer-(1B4M-Gd)(254): a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI. Bioconjug Chem 12:587\u2013593","journal-title":"Bioconjug Chem"},{"key":"6136_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/bs.enz.2022.08.005","volume":"51","author":"N Kondo","year":"2022","unstructured":"Kondo N (2022) DNA damage and biological responses induced by boron neutron capture therapy (BNCT). Enzymes 51:65\u201378","journal-title":"Enzymes"},{"key":"6136_CR19","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/pharmaceutics14051106","volume":"14","author":"N Kondo","year":"2022","unstructured":"Kondo N, Hirano F, Temma T (2022) Evaluation of 3-borono-l-phenylalanine as a water-soluble boron neutron capture therapy agent. Pharmaceutics 14:1106","journal-title":"Pharmaceutics"},{"key":"6136_CR20","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U (2016) Morgenstern A 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med 57:1941\u20131944","journal-title":"J Nucl Med"},{"key":"6136_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41467-023-35935-0","volume":"14","author":"YH Lai","year":"2023","unstructured":"Lai YH, Su CY, Cheng HW, Chu CY, Jeng LB, Chiang CS, Shyu WC, Chen SY (2023) Stem cell-nanomedicine system as a theranostic bio-gadolinium agent for targeted neutron capture cancer therapy. Nat Commun 14:285","journal-title":"Nat Commun"},{"key":"6136_CR22","doi-asserted-by":"publisher","DOI":"10.1039\/D0CC06557A","author":"M Lamba","year":"2021","unstructured":"Lamba M, Goswami A, Bandyopadhyay A (2021) A periodic development of BPA and BSH based derivatives in boron neutron capture therapy (BNCT). Chem Commun (Camb). https:\/\/doi.org\/10.1039\/D0CC06557A","journal-title":"Chem Commun (Camb)"},{"key":"6136_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijpharm.2006.04.009","volume":"320","author":"UM Le","year":"2006","unstructured":"Le UM, Cui Z (2006a) Biodistribution and tumor-accumulation of gadolinium (Gd) encapsulated in long-circulating liposomes in tumor-bearing mice for potential neutron capture therapy. Int J Pharm 320:96\u2013103","journal-title":"Int J Pharm"},{"key":"6136_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ijpharm.2006.01.002","volume":"312","author":"UM Le","year":"2006","unstructured":"Le UM, Cui Z (2006b) Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int J Pharm 312:105\u2013112","journal-title":"Int J Pharm"},{"key":"6136_CR25","first-page":"823","volume":"56","author":"W Lee","year":"2021","unstructured":"Lee W, Jung KH, Park JA, Kim JY, Lee YJ, Chang Y, Yoo J (2021) In vivo evaluation of PEGylated-liposome encapsulating gadolinium complexes for gadolinium neutron capture therapy. Biochem Biophys Res Commun 56:823\u2013829","journal-title":"Biochem Biophys Res Commun"},{"key":"6136_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.clon.2013.06.007","volume":"25","author":"ME Lomax","year":"2013","unstructured":"Lomax ME, Folkes LK, O\u2019Neill P (2013) Biological consequences of radiation-induced DNA damage: relevance to radiotherapy. Clin Oncol (r Coll Radiol) 25:578\u2013585","journal-title":"Clin Oncol (r Coll Radiol)"},{"key":"6136_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.601820","volume":"11","author":"TD Malouff","year":"2021","unstructured":"Malouff TD, Seneviratne DS, Ebner DK, Stross WC, Waddle MR, Trifiletti DM, Krishnan S (2021) Boron neutron capture therapy: a review of clinical applications. Front Oncol 11:601820","journal-title":"Front Oncol"},{"key":"6136_CR28","doi-asserted-by":"publisher","first-page":"54739","DOI":"10.1021\/acsami.1c16383","volume":"13","author":"N Meher","year":"2021","unstructured":"Meher N, Seo K, Wang S, Bidkar AP, Fogarty M, Dhrona S, Huang X, Tang R, Blaha C, Evans MJ, Raleigh DR, Jun YW, VanBrocklin HF, Desai TA, Wilson DM, Ozawa T, Flavell RR (2021) Synthesis and preliminary biological assessment of carborane-loaded theranostic nanoparticles to target prostate-specific membrane antigen. ACS Appl Mater Interfac 13:54739\u201354752","journal-title":"ACS Appl Mater Interfac"},{"key":"6136_CR29","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.3390\/cancers15164091","volume":"15","author":"A Monti Hughes","year":"2023","unstructured":"Monti Hughes A, Hu N (2023) Optimizing boron neutron capture therapy (BNCT) to treat cancer: an updated review on the latest developments on boron compounds and strategies. Cancers (Basel) 15:4091","journal-title":"Cancers (Basel)"},{"key":"6136_CR30","doi-asserted-by":"publisher","first-page":"6311","DOI":"10.1021\/acs.molpharmaceut.3c00726","volume":"20","author":"S Okada","year":"2023","unstructured":"Okada S, Nishimura K, Ainaya Q, Shiraishi K, Anufriev SA, Sivaev IB, Sakurai Y, Suzuki M, Yokoyama M, Nakamura H (2023) Development of a gadolinium-boron-conjugated albumin for MRI-guided neutron capture therapy. Mol Pharm 20:6311\u20136318","journal-title":"Mol Pharm"},{"key":"6136_CR31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.humpath.2006.11.012","volume":"38","author":"S Perner","year":"2007","unstructured":"Perner S, Hofer MD, Kim R, Shah RB, Li H, M\u00f6ller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696\u2013701","journal-title":"Hum Pathol"},{"key":"6136_CR32","first-page":"663","volume":"245","author":"HU Rashid","year":"2016","unstructured":"Rashid HU, Martines MAU, Jorge J, de Moraes PM, Umar MN, Khan K, Rehman HU (2016) Cyclen-based Gd3+ complexes as MRI contrast agents: relaxivity enhancement and ligand design. Bioorg Med Chem 245:663\u20135684","journal-title":"Bioorg Med Chem"},{"key":"6136_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12194-023-00758-7","volume":"17","author":"R Shamsabadi","year":"2024","unstructured":"Shamsabadi R, Baghani HR (2024) Impact of gadolinium concentration and cell oxygen levels on radiobiological characteristics of gadolinium neutron capture therapy technique in brain tumor treatment. Radiol Phys Technol 17:135\u2013142","journal-title":"Radiol Phys Technol"},{"key":"6136_CR34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1118\/1.596817","volume":"19","author":"JL Shih","year":"1992","unstructured":"Shih JL, Brugger RM (1992) Gadolinium as a neutron capture therapy agent. Med Phys 19:733\u2013744","journal-title":"Med Phys"},{"key":"6136_CR35","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1021\/cr941195u","volume":"98","author":"AH Soloway","year":"1998","unstructured":"Soloway AH, Tjarks W, Barnum BA, Rong FG, Barth RF, Codogni IM, Wilson JG (1998) The chemistry of neutron capture therapy. Chem Rev 98:1515","journal-title":"Chem Rev"},{"key":"6136_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2012.12.007","volume":"764","author":"L Telgmann","year":"2013","unstructured":"Telgmann L, Sperling M, Karst U (2013) Determination of gadolinium-based MRI contrast agents in biological and environmental samples: a review. Anal Chim Acta 764:1\u201316","journal-title":"Anal Chim Acta"},{"key":"6136_CR37","first-page":"830","volume":"161","author":"H Tokumitsu","year":"1999","unstructured":"Tokumitsu H, Ichikawa H, Fukumori Y (1999) Chitosan-gadopentetic acid complex nanoparticles for gadolinium neutron-capture therapy of cancer: preparation by novel emulsion-droplet coalescence technique and characterization. Pharm Res 161:830\u20131835","journal-title":"Pharm Res"},{"key":"6136_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/cmmi.1633","volume":"10","author":"C Truillet","year":"2015","unstructured":"Truillet C, Bouziotis P, Tsoukalas C, Brugi\u00e8re J, Martini M, Sancey L, Brichart T, Denat F, Boschetti F, Darbost U, Bonnamour I, Stellas D, Anagnostopoulos CD, Koutoulidis V, Moulopoulos LA, Perriat P, Lux F, Tillement O (2015) Ultrasmall particles for Gd-MRI and (68) Ga-PET dual imaging. Contrast Media Mol Imaging 10:309\u2013319","journal-title":"Contrast Media Mol Imaging"},{"key":"6136_CR39","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1021\/acs.molpharmaceut.9b00464","volume":"16","author":"S Wang","year":"2019","unstructured":"Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR (2019) Synthesis and initial biological evaluation of boron-containing prostate-specific membrane antigen ligands for treatment of prostate cancer using boron neutron capture therapy. Mol Pharm 16:3831\u20133841","journal-title":"Mol Pharm"},{"key":"6136_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.788770","volume":"12","author":"S Wang","year":"2022","unstructured":"Wang S, Zhang Z, Miao L, Li Y (2022) Boron neutron capture therapy: current status and challenges. Front Oncol 12:788770","journal-title":"Front Oncol"},{"key":"6136_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47\u201359","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6136_CR42","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.3390\/cancers15164060","volume":"15","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Chong Y, Liu Y, Pan J, Huang C, Sun Q, Liu Z, Zhu X, Shao Y, Jin C, Liu T (2023) A review of planned, ongoing clinical studies and recent development of BNCT in Mainland of China. Cancers (Basel) 15:4060","journal-title":"Cancers (Basel)"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06136-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T21:37:17Z","timestamp":1741815437000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06136-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["6136"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06136-7","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experimental procedures were conducted in accordance with the guidelines of the Institutional Animal Experimentation Ethics Committee of Anhui Medical University under Grant No. LLSC20232209.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"93"}}